Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China.
R & D Information China, AstraZeneca, 199 Liangjing Road, Pudong, Shanghai 201203, China; College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, Shenyang, Liaoning Province 110866, China.
Int J Antimicrob Agents. 2016 Mar;47(3):210-6. doi: 10.1016/j.ijantimicag.2015.12.019. Epub 2016 Feb 1.
Complicated intra-abdominal infection (cIAIs) are a common and important cause of morbidity worldwide. In this study, the clinical features, microbiological profiles, antimicrobial patterns and treatments of 3233 cIAI patients (mean age, 47.6 years; 54.7% male) with 3531 hospitalisations from 2008-2013 were retrospectively investigated. The most commonly isolated bacteria were Escherichia coli (47.6%), Klebsiella pneumoniae (16.9%), Enterococcus faecalis (10.4%) and Pseudomonas aeruginosa (8.8%). Ciprofloxacin, aminoglycoside (gentamicin), piperacillin/tazobactam and carbapenems exhibited activity against 53%, 76%, 88% and 100% of extended-spectrum β-lactamase (ESBL)-positive Enterobacteriaceae isolates, respectively. Pseudomonas aeruginosa isolates exhibited 100%, 95%, 88%, 71% and 76% susceptibility to aminoglycoside (gentamicin), ciprofloxacin, meropenem, imipenem and ceftazidime, respectively, and Enterococcus remained 100% susceptible to vancomycin and linezolid. β-Lactam antibacterials other than penicillin (specifically third-generation cephalosporins) and imidazole derivatives (ornidazole and metronidazole) were the most common first-line treatments. Patients subjected to regimen change after initial antibiotic treatment had predisposing conditions (e.g. older age, more severe co-morbidities) and a higher incidence of P. aeruginosa infection; in addition, these patients encountered a higher average cost of care and worse clinical outcomes compared with those without medication modification. Taken together, these findings indicate the importance of appropriate initial empirical therapy and suggest the use of combination therapy comprising cephalosporins and metronidazole.
复杂性腹腔内感染(cIAI)是全球范围内发病率高、较为常见的重要病因。本研究回顾性分析了 2008-2013 年期间 3233 例 cIAI 患者(平均年龄 47.6 岁,54.7%为男性)3531 例次住院的临床特征、微生物特征、抗菌模式和治疗情况。最常分离的细菌为大肠埃希菌(47.6%)、肺炎克雷伯菌(16.9%)、粪肠球菌(10.4%)和铜绿假单胞菌(8.8%)。环丙沙星、氨基糖苷类(庆大霉素)、哌拉西林/他唑巴坦和碳青霉烯类对 53%、76%、88%和 100%的产超广谱β-内酰胺酶(ESBL)肠杆菌科分离株具有活性。铜绿假单胞菌对氨基糖苷类(庆大霉素)、环丙沙星、美罗培南、亚胺培南和头孢他啶的敏感性分别为 100%、95%、88%、71%和 76%,粪肠球菌对万古霉素和利奈唑胺仍保持 100%的敏感性。除青霉素(特别是第三代头孢菌素)和咪唑衍生物(奥硝唑和甲硝唑)以外的β-内酰胺类抗菌药物是最常用的一线治疗药物。在初始抗生素治疗后进行方案更改的患者存在易患因素(如年龄较大、合并症较多),且铜绿假单胞菌感染的发生率较高;此外,与未调整药物治疗的患者相比,这些患者的平均治疗费用更高,临床结局更差。综上所述,这些发现表明适当的初始经验性治疗的重要性,并提示使用包含头孢菌素和甲硝唑的联合治疗方案。